Mylan announced the launch of Carboplatin Injection, the generic version of Bristol-Myers Squibb’s Paraplatin Injection.

Carboplatin Injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents and for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.

RELATED: Combo Tx Promising for Recurrent Ovarian Cancer

Carboplatin Injection will be available soon in 50mg/5mL, 150mg/15mL, 450mg/45mL, and 600mg/60mL in multi-dose vials.

For more information call (800) 796-9526 or visit